Welcomes Pathodynamics LLC.
Pathodynamics is led by a multi-disciplinary team combining expertise in oncology, genomics, computational biology, and bioinformatics. They enable precision oncology services by providing advanced knowledge about the functional significance of unclassified genetic variants to predict the right drug to use for a particular patient.
Pathodynamics harnesses the power of artificial intelligence and molecular simulation to be able to accurately predict the functional effects of genetic variants with >90% accuracy. We are applying this technology to helping to solve the problem of cancer drug resistance that caused over 90% of cancer deaths.
The faculty start-up Pathodynamics LLC has received a preliminary notice of an SBIR award. The team has been working with the MEC’s partner organization, ICAP, to commercialize this Mason-based technology.